inVentiv Health kept at buy by Jefferies

Jefferies & Co., Inc. security analyst David Windley reiterated the buy rating on inVentiv Health. Jefferies noted that acquisitions have contributed significantly to growth and should continue to at a smaller level. Jefferies believes inventive management is on the cusp of harvesting significant revenue synergies from these now integrated segments. Shares of the company were down 76 cents, or 2.54%, at $29.18 on volume of 251,681 shares. Three-month running averages were not available. (Nasdaq: VTIV)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.